PH12022550610A1 - Antibiotic combination therapies - Google Patents

Antibiotic combination therapies

Info

Publication number
PH12022550610A1
PH12022550610A1 PH1/2022/550610A PH12022550610A PH12022550610A1 PH 12022550610 A1 PH12022550610 A1 PH 12022550610A1 PH 12022550610 A PH12022550610 A PH 12022550610A PH 12022550610 A1 PH12022550610 A1 PH 12022550610A1
Authority
PH
Philippines
Prior art keywords
combination therapies
antibiotic combination
antibiotic
cefiderocol
colistin
Prior art date
Application number
PH1/2022/550610A
Other languages
English (en)
Inventor
Glenn E Dale
Marc Gitzinger
Christian Kemmer
Sergio Lociuro
Vincent Trebosc
Original Assignee
BioVersys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioVersys AG filed Critical BioVersys AG
Publication of PH12022550610A1 publication Critical patent/PH12022550610A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH1/2022/550610A 2019-09-12 2020-08-03 Antibiotic combination therapies PH12022550610A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US202062977659P 2020-02-17 2020-02-17
PCT/IB2020/000645 WO2021048610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Publications (1)

Publication Number Publication Date
PH12022550610A1 true PH12022550610A1 (en) 2023-03-13

Family

ID=72432957

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550610A PH12022550610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Country Status (17)

Country Link
US (6) US11351158B2 (cg-RX-API-DMAC7.html)
EP (3) EP4028001B1 (cg-RX-API-DMAC7.html)
JP (4) JP7804570B2 (cg-RX-API-DMAC7.html)
KR (1) KR102991225B1 (cg-RX-API-DMAC7.html)
CN (3) CN115052597B (cg-RX-API-DMAC7.html)
AU (2) AU2020347536B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004645A2 (cg-RX-API-DMAC7.html)
CA (2) CA3154317A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982067T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240818T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066936T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022003077A (cg-RX-API-DMAC7.html)
PH (1) PH12022550610A1 (cg-RX-API-DMAC7.html)
PL (1) PL4028001T3 (cg-RX-API-DMAC7.html)
RS (1) RS65681B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400250T1 (cg-RX-API-DMAC7.html)
WO (2) WO2021048610A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
WO2012106364A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
US10953070B2 (en) * 2014-07-25 2021-03-23 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
EP3189154B1 (en) * 2014-09-04 2023-03-22 Labrador Diagnostics LLC Pathogen and antimicrobial resistance testing
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
CN109789125B (zh) * 2016-08-16 2022-10-18 罗切斯特大学 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物
CA3055311A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Also Published As

Publication number Publication date
US20210077471A1 (en) 2021-03-18
AU2020344214B2 (en) 2026-01-22
ES2982067T3 (es) 2024-10-14
EP4028000A1 (en) 2022-07-20
WO2021048610A1 (en) 2021-03-18
BR112022004672A2 (pt) 2022-06-07
US11351158B2 (en) 2022-06-07
PL4028001T3 (pl) 2024-07-22
HRP20240818T1 (hr) 2024-10-11
HUE066936T2 (hu) 2024-09-28
JP2025176113A (ja) 2025-12-03
JP2022551228A (ja) 2022-12-08
US12257241B2 (en) 2025-03-25
US11766425B2 (en) 2023-09-26
US20220184048A1 (en) 2022-06-16
MX2022003077A (es) 2022-07-11
RS65681B1 (sr) 2024-07-31
CN115052597A (zh) 2022-09-13
US20240041845A1 (en) 2024-02-08
EP4420673A3 (en) 2024-11-06
SMT202400250T1 (it) 2024-07-09
KR20220103698A (ko) 2022-07-22
US11207305B2 (en) 2021-12-28
CN114980889A (zh) 2022-08-30
AU2020347536A1 (en) 2022-04-14
US20230132691A1 (en) 2023-05-04
JP7804570B2 (ja) 2026-01-22
BR112022004645A2 (pt) 2022-06-21
CN120860031A (zh) 2025-10-31
AU2020344214A1 (en) 2022-04-21
CA3154129A1 (en) 2021-03-18
AU2020347536B2 (en) 2025-09-25
EP4028001B1 (en) 2024-04-10
CA3154317A1 (en) 2021-03-18
US11833139B2 (en) 2023-12-05
WO2021048611A1 (en) 2021-03-18
KR102991225B1 (ko) 2026-07-14
JP7769605B2 (ja) 2025-11-13
US20250281469A1 (en) 2025-09-11
US20210077472A1 (en) 2021-03-18
JP2026016690A (ja) 2026-02-03
CN115052597B (zh) 2025-07-08
EP4028001C0 (en) 2024-04-10
JP2022548252A (ja) 2022-11-17
EP4028001A1 (en) 2022-07-20
EP4420673A2 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
NZ795271A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
EP4620471A3 (en) Treating amyotrophic lateral sclerosis with pridopidine
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2021006326A (es) Inhibidores de pcna.
EP4233911A3 (en) Wound healing medicament
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2020004072A (es) Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
MX2020001844A (es) Metodos y sistema para aparatos dentales homogeneos.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
EP4378535A3 (en) Antibiotic formulations for lower back pain
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
PH12021551949A1 (en) Cancer treatment